SCHEMBL2178488

SCHEMBL2178488

COc1ccccc1C(=O)Nc1ccc(-c2ccc3c(c2)C(=O)N(C(C(=O)O)C(C)C)C3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
ACHE P22303 3/20 0.47
ABCB1 P08183 1/20 0.46
GAA P10253 1/20 0.46
ATM Q13315 1/20 0.46
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CASP3 P42574 1/20 0.45
NR1H4 Q96RI1 1/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
AHR P35869 1/20 0.44
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KCNK3 O14649 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719150 1.00 LMNA (0.51) LMNATP53ACHEABCB1GAA
SCHEMBL2181618 0.93 LMNA (0.51) LMNATP53ACHEABCB1GAA
SCHEMBL13719033 0.91 MEN1 (0.48) LMNATP53ACHEABCB1GAA
SCHEMBL2180212 0.91 MEN1 (0.48) LMNATP53ACHEABCB1GAA
SCHEMBL2183053 0.91 MEN1 (0.49) LMNATP53GAAATMMAPT
SCHEMBL2183050 0.91 MEN1 (0.49) LMNATP53GAAATMMAPT
SCHEMBL13718929 0.90 LMNA (0.52) LMNATP53GAAATMMAPT
SCHEMBL2179032 0.90 LMNA (0.52) LMNATP53GAAATMMAPT
SCHEMBL13718999 0.90 TP53 (0.52) LMNATP53GAAATMMAPT
SCHEMBL2177068 0.87 SMO (0.53) LMNATP53ABCB1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885TP53 2093/4885ACHE 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.